Vascular Endothelial Growth Factor Receptor-2
-
Subject Areas on Research
- A comparison of antiangiogenic therapies for the prevention of liver metastases.
- Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression.
- Aging is not associated with bone marrow-resident progenitor cell depletion.
- An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer.
- Anchorage of VEGF to the extracellular matrix conveys differential signaling responses to endothelial cells.
- Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators.
- Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.
- Cell-Demanded VEGF Release via Nanocapsules Elicits Different Receptor Activation Dynamics and Enhanced Angiogenesis
- Circulating progenitor cells can be reliably identified on the basis of aldehyde dehydrogenase activity.
- Common endothelial progenitor cell assays identify discrete endothelial progenitor cell populations.
- Conditional HIF-1 induction produces multistage neovascularization with stage-specific sensitivity to VEGFR inhibitors and myeloid cell independence.
- Cytokine-induced mobilization of circulating endothelial progenitor cells enhances repair of injured arteries.
- Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity.
- Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing.
- Effect of pazopanib on tumor microenvironment and liposome delivery.
- Efficacy of sunitinib and radiotherapy in genetically engineered mouse model of soft-tissue sarcoma.
- Endoglin interacts with VEGFR2 to promote angiogenesis.
- From man to fish: What can Zebrafish tell us about ApoL1 nephropathy?
- Hypoxic Gene Expression of Donor Bronchi Linked to Airway Complications after Lung Transplantation.
- IQGAP1, a novel vascular endothelial growth factor receptor binding protein, is involved in reactive oxygen species--dependent endothelial migration and proliferation.
- Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
- Late outgrowth endothelial progenitor cells in patients with age-related macular degeneration.
- Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy.
- Neuropilin-1 functions as a VEGFR2 co-receptor to guide developmental angiogenesis independent of ligand binding.
- NgBR is essential for endothelial cell glycosylation and vascular development.
- Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.
- Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors.
- Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis.
- Rapid, reversible modulation of blood-brain barrier P-glycoprotein transport activity by vascular endothelial growth factor.
- Reduction of Stat3 activity attenuates HIV-induced kidney injury.
- Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts.
- Regulation of blood vessel versus lymphatic vessel growth in the cornea.
- Relationship of smoking and fibrosis in patients with chronic hepatitis C.
- Synergistic induction of mitogen-activated protein kinase phosphatase-1 by thrombin and epidermal growth factor requires vascular endothelial growth factor receptor-2.
- Synergy between tumor immunotherapy and antiangiogenic therapy.
- Targeted inhibition of VEGF receptor 2: an update on ramucirumab.
- Targeting CXCR4-dependent immunosuppressive Ly6Clow monocytes improves antiangiogenic therapy in colorectal cancer.
- Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis.
- The Flk1-myr::mCherry mouse as a useful reporter to characterize multiple aspects of ocular blood vessel development and disease.
- The effect of vascular endothelial growth factor (VEGF) presentation within fibrin matrices on endothelial cell branching.
- The effects of ZD6474, an inhibitor of VEGF signaling, on cutaneous wound healing in mice.
- The phosphorylation of vascular endothelial growth factor receptor-2 (VEGFR-2) by engineered surfaces with electrostatically or covalently immobilized VEGF.
- Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level.
- Tumor vascular permeability to a nanoprobe correlates to tumor-specific expression levels of angiogenic markers.
- VEGF and soluble VEGF receptor-1 (sFlt-1) distributions in peripheral arterial disease: an in silico model.
- VEGF internalization is not required for VEGFR-2 phosphorylation in bioengineered surfaces with covalently linked VEGF.
- Vascular endothelial growth factor induces abnormal microvasculature in the endoglin heterozygous mouse brain.
- Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression.
- Vascular-targeted photothermal therapy of an orthotopic murine glioma model.